European Medicines Agency to perform regulatory review of avacopan for ANCA-associated vasculitis

Regulatory review for this orally administered selective complement 5a receptor inhibitor will mainly be based on data from the Phase-III ADVOCATE trial which found avicopan to be superior to prednisone for sustaining remission, and also with reduced toxicity.

Source:

Biospace Inc.